Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG4040 + SOC in Chronic Genotype 1 Hepatitis C
NCT01055821Phase 2Completed
- Sponsor
- Transgene SA
- Start
- May 2010
- Primary completion
- Oct 2012
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of TG4040 in hepatitis C (HCV) (3 arms), sponsored by Transgene SA. Primary endpoint: Complete Early Virologic Response at 12 weeks. Started May 2010; status: completed.
02
Drugs
TG4040
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01055821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01055821.